{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:51:19Z","timestamp":1791831079055,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":3045,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/jto.0b013e31811f4719","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T09:30:39Z","timestamp":1209893439000},"page":"745-750","source":"Crossref","is-referenced-by-count":25,"title":["Phase I Trial of Motexafin Gadolinium in Combination with Docetaxel and Cisplatin for the Treatment of Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"2","author":[{"suffix":"Jr","given":"William N.","family":"William","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G.","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun W.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie S.","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See-Chun","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e31811f4719_bib1","first-page":"739","article-title":"A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging","volume":"5","author":"Rosenthal","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31811f4719_bib2","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2002.07.500","article-title":"Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points","volume":"20","author":"Mehta","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib3","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1073\/pnas.93.13.6610","article-title":"Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI","volume":"93","author":"Young","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1097\/JTO.0b013e31811f4719_bib4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0360-3016(99)00274-6","article-title":"In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer","volume":"45","author":"Miller","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31811f4719_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0022-3565(24)29612-9","article-title":"Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy","volume":"297","author":"Woodburn","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/JTO.0b013e31811f4719_bib6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(01)01810-7","article-title":"Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species","volume":"51","author":"Magda","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e31811f4719_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.cco.0000142073.29850.98","article-title":"Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer","volume":"16","author":"Evens","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib8","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1046\/j.1432-1327.2000.01701.x","article-title":"Physiological functions of thioredoxin and thioredoxin reductase","volume":"267","author":"Arner","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1097\/JTO.0b013e31811f4719_bib9","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1158\/0008-5472.CAN-04-4099","article-title":"Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines","volume":"65","author":"Magda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1097\/JTO.0b013e31811f4719_bib10","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1074\/jbc.M511373200","article-title":"Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase","volume":"281","author":"Hashemy","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e31811f4719_bib11","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1200\/JCO.2001.19.7.2074","article-title":"Multicenter phase Ib\/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases","volume":"19","author":"Carde","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","article-title":"Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases","volume":"21","author":"Mehta","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib13","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1200\/jco.2006.24.18_suppl.7014","article-title":"Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a phase III trial (Abstract)","volume":"24","author":"Mehta","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","article-title":"Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial","volume":"22","author":"Meyers","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib15","first-page":"489","article-title":"Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: pooled analysis of two randomized phase 3 trials","volume":"8","author":"Shapiro","year":"2006","journal-title":"Neurooncology"},{"key":"10.1097\/JTO.0b013e31811f4719_bib16","first-page":"3215","article-title":"Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin","volume":"7","author":"Miller","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e31811f4719_bib17","first-page":"466","article-title":"Motexafin gadolinium (MGd) increases tumor response to chemotherapy in Lewis lung cancer (LLC) animal model (Abstract)","volume":"21","author":"Miller","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib18","first-page":"917","article-title":"The redox mediator motexafin gadolinium (MGd) enhances the activity of several chemotherapy drugs (Abstract)","volume":"22","author":"Magda","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"18 Suppl","key":"10.1097\/JTO.0b013e31811f4719_bib20","first-page":"13155","article-title":"A phase I trial combining motexafin gadolinium (MGd) with docetaxel in the treatment of advanced solid tumors (Abstract)","volume":"24","author":"Pandya","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1097\/JTO.0b013e31811f4719_bib21","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/jco.2005.23.16_suppl.3164","article-title":"Phase I trial of motexafin gadolinium (MGd) and docetaxel (D) chemotherapy in the treatment of advanced solid tumors (Abstract)","volume":"23","author":"Petro","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e31811f4719_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/0091270004271946","article-title":"Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme","volume":"45","author":"Miles","year":"2005","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415313058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415313058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:45:23Z","timestamp":1738201523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415313058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1556086415313058"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e31811f4719","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}